Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Accreditation Certification ISQua EEA

 
The Ministry of Public Health (MOPH) is proud to announce the reception of the prestigious Award by the International Society for Quality in Health Care – External Evaluation Association (ISQua EEA) for the Accreditation Standards of Hospitals in Lebanon 2022 Edition.

This development marks a crucial step forward for quality improvement and the enhancement of patient safety culture with internationally recognized standards.

Given the principal importance of improving healthcare management, quality of care, and patient safety in our hospitals, especially in these challenging times in Lebanon, we are committed to maintaining the accreditation process as an integral part of continuous healthcare improvement in Lebanon, with teams/trainers dedicated to improving care in hospitals, 44 trained surveyors and more than 500 health professionals from all hospitals in Lebanon currently being trained.

Special recognition goes to Dr. Walid Ammar for his leadership and guidance in transforming the hospital accreditation system in Lebanon.

We would like to extend our gratitude to Dr. Fadi El-Jardali and his team for their exceptional work in revising and improving the accreditation standards and tools. We also thank Dr. Ali Elhaj for his contributions during the initial phase of standards revision.

We are deeply grateful the financial support of AFD, to the Haute Autorité de Santé (HAS France) and all individuals who offered their advice and technical support, especially Dr. Bruno Lucet for his complete support during all the preparation process for the ISQua EEA certification.

We express our sincere appreciation to the Comité Technique d’Accréditation Hospitalière (CTAH) for their valuable feedback and suggestions, as well as the National Hospital Accreditation Committee (CNAH) including the main stakeholders: Ecole Supérieure des Affaires (ESA), Syndicate of Hospitals, Order of Physicians, Order of Nurses, Order of Pharmacists, Order of Midwives, Lebanese National Committee of Blood Transfusion, Army Medical Services, NSSF, MFE, and various faculties of medicine. We would like to acknowledge their contributions and their unwavering support.

Additionally, we extend our warm thanks to the national experts for their invaluable feedback and suggestions on the standards.

A special thanks to Perrine Malaud Wakim and the team of Pôle Santé at for their continuous dedication and support.

#Healthcare #Quality #Accreditation #Standards # Patient Safety Culture #MOPH #ESA #AFD #HAS #CNAH #CTAH #
    ...
    62
    ...
ATC Name B/G Ingredients Dosage Form Price
L03AB11 PEGASYS BioTech Peginterferon alfa-2a - 180mcg/0.5ml 180mcg/0.5ml Injectable solution L.L
L01FA01 TRUXIMA BioTech Rituximab - 100mg/10ml 100mg/10ml Injectable concentrate for solution 31,102,895 L.L
L04AA33 ENTYVIO BioTech Vedolizumab - 108mg 108mg Injectable solution 92,478,560 L.L
L01FA01 ZYTUX BioTech Rituximab - 100mg/10ml 100mg/10ml Injectable concentrate for solution 16,463,240 L.L
L04AA36 OCREVUS BioTech Ocrelizumab - 300mg/10ml 300mg/10ml Injectable concentrate for solution 547,517,314 L.L
L01FA01 MABIXEN 500 BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrate for solution 136,761,210 L.L
L04AA36 OCREVUS BioTech Ocrelizumab - 920mg/23ml 920mg/23ml Injectable solution 1,095,034,629 L.L
L01FA01 MABIXEN 500 BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrate for solution 74,718,320 L.L
L01FA01 MABTHERA BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrated solution 80,211,932 L.L
L01FA01 RITUXIREL BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrated solution 45,258,360 L.L
L01FA01 RIXATHON BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrate for solution 66,951,899 L.L
L01FD01 TRASTUREL BioTech Trastuzumab - 440mg 440mg Injectable lyophilised powder L.L
L01FA01 RIXATHON BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrate for solution 116,417,745 L.L
L01FG01 BEVACIREL BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable solution L.L
L01FA01 RUXIENCE BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrate for solution 59,148,151 L.L
L01FG01 BEVACIREL BioTech Bevacizumab - 100mg/4ml 100mg/4ml Injectable solution L.L
L01FA01 TRUXIMA BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrate for solution 69,144,591 L.L
L04AA52 KESIMPTA BioTech Ofatumumab - 20mg/0.4ml 20mg/0.4ml Injectable solution 96,542,598 L.L
L04AB01 ETANERREL BioTech Etanercept - 25mg/0.5ml 25mg/0.5ml Injectable solution L.L
L01FA01 ZYTUX BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrate for solution 27,724,196 L.L
L04AB01 ALTEBREL BioTech Etanercept - 50mg/1ml 50mg/1ml Injectable solution 14,833,767 L.L
L01FA01 RITUXIREL BioTech Rituximab - 100mg/10ml 100mg/10ml Injectable concentrated solution L.L
A16AB04 FABRAZYME BioTech Agalsidase beta - 35mg 35mg Injectable powder for concentrate for solution 295,038,213 L.L
L01FA03 GAZYVA BioTech Obinutuzumab - 1000mg/40ml 1000mg/40ml Injectable concentrate for solution 314,437,416 L.L
L04AB01 ENBREL BioTech Etanercept - 50mg 50mg Injectable solution 52,197,598 L.L
L01FA01 RITUXIREL BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrated solution L.L
L01FB01 BESPONSA FOR INJECTION BioTech Inotuzumab Ozogamicin - 0.9mg 0.9mg Injectable powder for suspension 921,176,511 L.L
L04AB01 ENBREL BioTech Etanercept - 50mg 50mg Injectable solution 52,197,598 L.L
A16AB07 MYOZYME BioTech Alglucosidase alfa, recombinant human acid - 50mg 50mg Injectable powder for concentrate for solution 56,536,307 L.L
L01FC01 DARZALEX BioTech Daratumumab - 400mg/20ml 400mg/20ml Injectable concentrate for solution 171,503,274 L.L
    ...
    62
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026